John Reed
Chief Executive Officer at SYNTHORX, INC.
Net worth: 48 406 $ as of 30/03/2024
Profile
John C. Reed founded Idun Pharmaceuticals, Inc. and Apoptos, Inc. Currently, Dr. Reed is EVP & Global Head-Research & Development at Sanofi and President at Principia Biopharma, Inc. and President & Director at Synthorx, Inc. (both are subsidiaries of Sanofi). He is also on the board of BIOCOM. In his past career John C. Reed occupied the position of Head-Roche Pharma Research & Early Development at Roche Holding AG, President, Chief Executive Officer & Professor at Sanford Burnham Prebys Medical Discovery Institute, Assistant Director at the University of Pennsylvania, Associate Member at the University of California San Diego and Associate Member at Whitaker Institute of Biomedical Engineering. He received an undergraduate degree from the University of Virginia and a doctorate from Perelman School of Medicine.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
JOHNSON & JOHNSON
0.00% | 14/02/2024 | 306 ( 0.00% ) | 48 406 $ | 30/03/2024 |
John Reed active positions
Companies | Position | Start |
---|---|---|
SYNTHORX, INC. | Chief Executive Officer | - |
PRINCIPIA BIOPHARMA INC. | President | - |
JOHNSON & JOHNSON | Corporate Officer/Principal | - |
BIOCOM
BIOCOM Miscellaneous Commercial ServicesCommercial Services BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA. | Director/Board Member | 23/06/2011 |
Former positions of John Reed
Companies | Position | End |
---|---|---|
SANOFI | Chief Tech/Sci/R&D Officer | 12/02/2023 |
ROCHE HOLDING AG | Corporate Officer/Principal | 01/04/2018 |
CLOVIS ONCOLOGY, INC. | Director/Board Member | 13/02/2013 |
IONIS PHARMACEUTICALS, INC. | Director/Board Member | 11/02/2013 |
Whitaker Institute of Biomedical Engineering | Corporate Officer/Principal | 31/12/2012 |
Training of John Reed
University of Virginia | Undergraduate Degree |
Perelman School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 4 |
---|---|
JOHNSON & JOHNSON | Health Technology |
ROCHE HOLDING AG | Health Technology |
IONIS PHARMACEUTICALS, INC. | Health Technology |
SANOFI | Health Technology |
Private companies | 11 |
---|---|
Repros Therapeutics, Inc.
Repros Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Repros Therapeutics, Inc. is a development stage biopharmaceutical company, which focuses on the development of drugs to treat hormonal and reproductive systems disorders. Its products include Enclomiphene and Proellex. The company was founded on August 20, 1987 and is headquartered in The Woodlands, TX. | Health Technology |
Pharmion Corp.
Pharmion Corp. Pharmaceuticals: MajorHealth Technology Pharmion Corp. engages in the development and commercialization of products for the treatment of hematology and oncology patients. It has operations in Switzerland, Israel, and Philippines. The company was founded by Patrick J. Mahaffy in 1999 and is headquartered in Boulder, CO. | Health Technology |
Idun Pharmaceuticals, Inc.
Idun Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Idun Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the discovery and development of human therapeutics to control apoptosis. The company was founded by John C. Reed, Robert H. Horvitz, and Lawrence C. Fritz in March 1993 and is headquartered in San Diego, CA. | Health Technology |
Apoptos, Inc.
Apoptos, Inc. Pharmaceuticals: MajorHealth Technology Apoptos, Inc. discovers and develops small molecule anticancer drugs. The company focuses in drug therapies that directly induce tumor cell apoptosis. It was founded in 2007 and is headquartered in San Diego, CA | Health Technology |
Principia Biopharma, Inc.
Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
Stratagene Corp.
Stratagene Corp. Medical SpecialtiesHealth Technology Stratagene Corp. researches, develops and markets diagnostic products and technologies for life science research. The company's products are used in the research of amplification, cell biology, cloning, microarrays, nucleic acid analysis, protein function and analysis, and quantitative PCR. Its clients include the industrial and government research sectors. The firm sells its products in more than 60 countries. Stratagene was founded in 1984 and is located in La Jolla, CA. | Health Technology |
BIOCOM
BIOCOM Miscellaneous Commercial ServicesCommercial Services BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA. | Commercial Services |
Sanford Burnham Prebys Medical Discovery Institute
Sanford Burnham Prebys Medical Discovery Institute Medical/Nursing ServicesHealth Services Sanford Burnham Prebys Medical Discovery Institute conducts and translates biological research programs. The firm offers tumor initiation and maintenance, cancer metabolism and signaling network, tumor microenvironment and cancer immunology, degenerative disease, development/aging/regeneration, immunity and pathogenesis, human genetic, cardiovascular metabolism, integrative metabolism, metabolism genomic control, bioinformatics and structural biology programs. The company was founded by William Fishman and Lillian Fishman in 1976 and is headquartered in La Jolla, CA. | Health Services |
CONNECT
CONNECT Miscellaneous Commercial ServicesCommercial Services CONNECT creates and scales companies in the technology and life sciences sectors. It creates an environment in which entrepreneurs and C-suite executives have access to the people, capital, and technology resources. The organization was founded in 1985 and is headquartered in San Diego, CA. | Commercial Services |
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
Synthorx, Inc.
Synthorx, Inc. BiotechnologyHealth Technology Synthorx, Inc. focuses on prolonging and improving lives of cancer and autoimmune disorder patients. Its product pipeline is comprised of THOR-707, IL-2 Synthorin, IL-10 Synthorin, and IL-15 Synthorin. The company was founded by Floyd E. Romesberg and Court R. Turner in 2014 and is headquartered in La Jolla, CA. | Health Technology |
- Stock Market
- Insiders
- John Reed